Pfizer wins fast-track status for breast cancer drug palbociclib

04/12/2013 | PharmaTimes (U.K.)

The FDA granted breakthrough therapy designation to Pfizer's palbociclib as possible treatment for breast cancer patients. The decision was based on preliminary midstage trial results showing palbociclib's efficacy in improving median progression free survival in patients, in combination with letrozole.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY